Port Elizabeth
Port Elizabeth
Port Elizabeth, South Africa21 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06) | Infections, RNA Virus Infections, influenza, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease | Active, not recruiting | Phase 3 | 2026-09-17 | NCT07159763 | |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | Active, not recruiting | Phase 3 | 2026-09-14 | NCT06065748 | |
| A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) | Non Squamous Non Small Cell Lung Cancer | Active, not recruiting | Phase 3 | 2026-09-10 | NCT06687369 | |
| Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-09-10 | NCT04493853 | |
| A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) | Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-09-03 | NCT04035486 | |
| A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, kidney cancer, kidney disorder, liver disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, urinary system disorder | Active, not recruiting | Phase 2 | 2026-09-02 | NCT05879822 | |
| Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults | Actinomycetales infectious disease, Bacterial Infections and Mycoses, Infections, bacterial infectious disease, gram-positive bacterial infections, mycobacterial infectious disease, tuberculosis | Active, not recruiting | Phase 3 | 2026-08-28 | NCT06062238 | |
| A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-08-24 | NCT05104866 | |
| Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients | Blood-Borne Infections, Genital Diseases, HIV infectious disease, Infections, RNA Virus Infections, Urogenital Diseases, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, sexually transmitted disease, uterine carcinosarcoma, viral infectious disease, viral sexually transmitted disease | Active, not recruiting | Phase 3 | 2026-08-21 | NCT02362503 | |
| A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma | skin squamous cell carcinoma | Active, not recruiting | Phase 2 | 2026-08-17 | NCT05888844 | |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-08-10 | NCT05952557 | |
| Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-07-30 | NCT04784715 | |
| Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis | Actinomycetales infectious disease, Bacterial Infections and Mycoses, Infections, bacterial infectious disease, gram-positive bacterial infections, lung disorder, mycobacterial infectious disease, pulmonary tuberculosis, respiratory system disorder, respiratory tract infectious disorder, tuberculosis | Active, not recruiting | Phase 2 | 2026-06-24 | NCT06058299 | |
| Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis | Actinomycetales infectious disease, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, Infections, Neuroinflammatory Diseases, Tuberculosis, Central Nervous System, Tuberculosis, Extrapulmonary, bacterial infectious disease, bacterial meningitis, central nervous system disorder, central nervous system infectious disorder, gram-positive bacterial infections, meningeal tuberculosis, meningitis, mycobacterial infectious disease, nervous system disorder, tuberculosis | Recruiting | Phase 3 | 2026-06-24 | NCT04145258 | |
| A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab)) | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Phase 2 | 2026-06-23 | NCT05731128 | |
| A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-06-17 | NCT04961996 | |
| D9319C00001- 1L OC Mono Global RCT | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Active, not recruiting | Phase 3 | 2026-03-02 | NCT04884360 | |
| Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment | AIDS, Actinomycetales infectious disease, Bacterial Infections and Mycoses, Blood-Borne Infections, Genital Diseases, HIV infectious disease, Infections, RNA Virus Infections, Slow Virus Diseases, Urogenital Diseases, bacterial infectious disease, drug-resistant tuberculosis, gram-positive bacterial infections, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, multidrug-resistant tuberculosis, mycobacterial infectious disease, sexually transmitted disease, tuberculosis, uterine carcinosarcoma, viral infectious disease, viral sexually transmitted disease | Recruiting | Not applicable | 2025-10-20 | NCT05671718 | |
| Reducing Mortality in Adults With Advanced HIV Disease (REVIVE) | AIDS, Blood-Borne Infections, Genital Diseases, HIV infectious disease, Infections, RNA Virus Infections, Slow Virus Diseases, Urogenital Diseases, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, sexually transmitted disease, uterine carcinosarcoma, viral infectious disease, viral sexually transmitted disease | Recruiting | Phase 3 | 2025-09-03 | NCT05580666 | |
| Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2025-07-16 | NCT04915755 | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | DNA Virus Infections, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Infections, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Tumor Virus Infections, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, adenoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, classic Hodgkin lymphoma, cutaneous neuroendocrine carcinoma, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, head and neck cancer, immune system disorder, immunoproliferative disorder, kidney cancer, kidney disorder, lung disorder, lung neoplasm, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant mesothelioma, melanocytic neoplasm, melanoma, mesothelial neoplasm, mesothelioma, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, non-Hodgkin lymphoma, non-small cell lung carcinoma, pleural neoplasm, polyomavirus infectious disease, primitive neuroectodermal tumor, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, skin squamous cell carcinoma, small cell carcinoma, transitional cell carcinoma, urinary system disorder, urothelial carcinoma, uterine disorder, viral infectious disease | Active, not recruiting | Phase 1 | 2025-02-03 | NCT03212404 |